Sunshine Biopharma Inc. (OTC: SBFM) announced yesterday breaking news that, "it has ordered a new batch of Adva-27a from its manufacturer in China. The material will be delivered to the laboratories of Sunshine Biopharma's drug development partner in Montreal (Canada). Sunshine plans to use the material to conduct testing on various types of cancer cells that overproduce Topoisomerase II (TopII). Following these cell culture studies, Sunshine will proceed to performing studies on mice harboring tumors of human origin with TopII amplification. TopII is an essential cell cycle enzyme that is amplified in approximately 4% of all human cancers.
'All cancer types that have amplification of the Topoisomerase II gene are potential new targets for our Adva-27a,' said Dr. Steve Slilaty, CEO of Sunshine Biopharma. 'This is an additional application for our Adva-27a beyond the original multidrug resistance indication,' he added.
About Sunshine Biopharma: In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University's Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual property pertaining to Adva-27a."
Sunshine Biopharma Inc. (OTC: SBFM), Onconova Therapeutics, Inc. (NASDAQ: ONTX), Ocugen, Inc. (NASDAQ: OCGN), Advaxis, Inc. (NASDAQ: ADXS), Moleculin Biotech, Inc. (NASDAQ: MBRX)